Systemically administered allogeneic mesenchymal stem cells do not aggravate the progression of precancerous lesions: a new biosafety insight

Bruna, Flavia; Plaza, Anita; Arango, Martha Inés Torres; Espinoza, Iris; Conget, Paulette

doi:10.1186/s13287-018-0878-1

Cited by 19 publications

(14 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, it has been shown that MSC can actually inhibit the progression of cancerous tumors. In hamsters with induced premalignant stages of squamous cell carcinoma of the mouth cavity, they decreased the progression of lesions (except for the largest doses) [117]. Less optimistic are the latest discoveries in the field of MSC immunogenicity.…”

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cells—Potential Applications in Kidney Diseases

Bochon¹,

Kozubska²,

Surygała³

et al. 2019

IJMS

View full text Add to dashboard Cite

Mesenchymal stem cells constitute a pool of cells present throughout the lifetime in numerous niches, characteristic of unlimited replication potential and the ability to differentiate into mature cells of mesodermal tissues in vitro. The therapeutic potential of these cells is, however, primarily associated with their capabilities of inhibiting inflammation and initiating tissue regeneration. Owing to these properties, mesenchymal stem cells (derived from the bone marrow, subcutaneous adipose tissue, and increasingly urine) are the subject of research in the settings of kidney diseases in which inflammation plays the key role. The most advanced studies, with the first clinical trials, apply to ischemic acute kidney injury, renal transplantation, lupus and diabetic nephropathies, in which beneficial clinical effects of cells themselves, as well as their culture medium, were observed. The study findings imply that mesenchymal stem cells act predominantly through secreted factors, including, above all, microRNAs contained within extracellular vesicles. Research over the coming years will focus on this secretome as a possible therapeutic agent void of the potential carcinogenicity of the cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Mesenchymal Stem Cells—Potential Applications in Kidney Diseases

Bochon¹,

Kozubska²,

Surygała³

et al. 2019

IJMS

View full text Add to dashboard Cite

show abstract

“…Samples were classified according to the revised criteria given by the World Health Organization (2005). Three independent observers performed histological analyses blind; one of them is a pathologist expert in oral diseases 57 , 58 .…”

Section: Methodsmentioning

confidence: 99%

SPINK7 expression changes accompanied by HER2, P53 and RB1 can be relevant in predicting oral squamous cell carcinoma at a molecular level

Pennacchiotti

Valdés-Gutiérrez

González‐Arriagada

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The oral squamous cell carcinoma (OSCC), which has a high morbidity rate, affects patients worldwide. Changes in SPINK7 in precancerous lesions could promote oncogenesis. Our aim was to evaluate SPINK7 as a potential molecular biomarker which predicts OSCC stages, compared to: HER2, TP53, RB1, NFKB and CYP4B1. This study used oral biopsies from three patient groups: dysplasia (n = 33), less invasive (n = 28) and highly invasive OSCC (n = 18). The control group consisted of clinically suspicious cases later to be confirmed as normal mucosa (n = 20). Gene levels of SPINK7, P53, RB, NFKB and CYP4B1 were quantified by qPCR. SPINK7 levels were correlated with a cohort of 330 patients from the TCGA. Also, SPINK7, HER2, TP53, and RB1, were evaluated by immunohistofluorescence. One-way Kruskal–Wallis test and Dunn's post-hoc with a p < 0.05 significance was used to analyze data. In OSCC, the SPINK7 expression had down regulated while P53, RB, NFKB and CYP4B1 had up regulated (p < 0.001). SPINK7 had also diminished in TCGA patients (p = 2.10e-6). In less invasive OSCC, SPINK7 and HER2 proteins had decreased while TP53 and RB1 had increased with respect to the other groups (p < 0.05). The changes of SPINK7 accompanied by HER2, P53 and RB1 can be used to classify the molecular stage of OSCC lesions allowing a diagnosis at molecular and histopathological levels.

show abstract

“…Five representative optical sections by sample (n=6/group) were photographed using 60X magnification. The images obtained per field of each sample, were processed with the same conditions and the positive protein signal (pixels intensity) was analyzed and quantified using Fiji Image J software (NIH, USA) 56,57 .…”

Section: A-b)mentioning

confidence: 99%

SPINK7 Expression Changes Accompanied by HER2, P53 and RB1 Can Be Relevant to Predict Oral Squamous Cell Carcinoma at Molecular Level

Pennacchiotti

Garrido

González‐Arriagada

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

The oral squamous cell carcinoma (OSCC) affects patients worldwide with a high morbidity rate. Changes of SPINK7 in precancerous lesions could promote oncogenesis. Our aim was to evaluate SPINK7 as a potential molecular biomarker predictive of OSCC stages, compared with: HER2, TP53, RB1, NFKB and CYP4B1. Oral biopsies from patients with dysplasia (n=33), less invasive (n=28) and highly invasive OSCC (n=18) were used. 20 cases with a clinical suspicion but normal mucosa confirmed were the control. Gene levels of SPINK7, P53, RB, NFKB and CYP4B1 were quantified by qPCR. SPINK7 levels were correlated with a cohort of 330 patients from the TCGA. Also, SPINK7, HER2, TP53, and RB1, were evaluated by immunohistofluorescence. One-way Kruskal-Wallis test and Dunn's post-hoc with a p<0.05 significance was used to data analyze. In OSCC, SPINK7 expression was down regulated and P53, RB, NFKB and CYP4B1 were up regulated (p<0.001). Also, SPINK7 was diminished in TCGA patients (p=2.10e-6). In less invasive OSCC, SPINK7 and HER2 proteins were decreased and TP53 and RB1 increased respect to others groups (p<0.05). Our results suggest that SPINK7 changes accompanied of HER2, P53 and RB1 can be used to classify the molecular stage of OSCC lesions, allowing a diagnosis to molecular and histopathological level.

show abstract

Systemically administered allogeneic mesenchymal stem cells do not aggravate the progression of precancerous lesions: a new biosafety insight

Cited by 19 publications

References 33 publications

Mesenchymal Stem Cells—Potential Applications in Kidney Diseases

Mesenchymal Stem Cells—Potential Applications in Kidney Diseases

SPINK7 expression changes accompanied by HER2, P53 and RB1 can be relevant in predicting oral squamous cell carcinoma at a molecular level

SPINK7 Expression Changes Accompanied by HER2, P53 and RB1 Can Be Relevant to Predict Oral Squamous Cell Carcinoma at Molecular Level

Contact Info

Product

Resources

About